The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Aussie airline Regional Express’s (REX) subsidiary Pel-Air has signed a 10-year contract with New South Wales Ambulance
  • The airline will provide aerial transport for medical personnel and patients in New South Wales’ regional communities
  • Pel-Air’s contract with the New South Wales Ambulance will begin in January 2022
  • Regional Express’ share price is currently trading at $1.08 apiece

Regional Express (REX) subsidiary airline Pel-Air has entered into a contract with the New South Wales Ambulance. The contract’s operational phase will begin in January 2022, and has s expected to last for 10 years.

Under the contract, Pel-Air will provide the NSW Ambulance with 5 fixed-wing aircraft, pilots, and engineering support. This will enable the aerial transport of NSW Ambulance’s medical personnel and patients in NSW’s regional communities.

In 2009, Pel-Air was awarded a similar deal with Ambulance Victoria, who recently extended the contract until 2023.

Pel-Air Chairman, the Honourable John Sharp, AM, commented on the contract. “This award is a clear recognition of Pel-Air’s undisputed ability to provide safe, reliable, and high-quality aeromedical services on fixed-wing aircraft, at the most competitive prices.”

Regional Express shares are currently trading at $1.08 apiece.

rex by the numbers
More From The Market Online

Argent Biopharma executes global licence for non-core Cannabis genetics

Argent BioPharma has entered into a worldwide licensing agreement with TPI for the commercial development of…

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…